Effector Therapeutics Inc (EFTR)

Currency in USD
0.001
0.000(0.00%)
Closed·
EFTR Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week Low
Fair Value
Day's Range
0.0010.001
52 wk Range
0.0010.060
Key Statistics
Prev. Close
-
Open
0.001
Day's Range
0.001-0.001
52 wk Range
0.001-0.06
Volume
-
Average Volume (3m)
513
1-Year Change
-98.18%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EFTR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Locust Walk Acquisition Corp Company Profile

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Compare EFTR to Peers and Sector

Metrics to compare
EFTR
Peers
Sector
Relationship
P/E Ratio
0.0x−4.7x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
0.0x2.1x2.6x
Price / LTM Sales
0.0x9.6x3.2x
Upside (Analyst Target)
0.0%178.3%41.9%
Fair Value Upside
Unlock6.7%4.3%Unlock

Earnings

Latest Release
May 09, 2024
EPS / Forecast
-2.16 / -3.00
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

EFTR Income Statement

FAQ

What Stock Exchange Does Locust Walk Acquisition Trade On?

Locust Walk Acquisition is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Locust Walk Acquisition?

The stock symbol for Locust Walk Acquisition is "EFTR."

What Is the Locust Walk Acquisition Market Cap?

As of today, Locust Walk Acquisition market cap is 4.70K.

What Is Locust Walk Acquisition's Earnings Per Share (TTM)?

The Locust Walk Acquisition EPS (TTM) is -12.42.

From a Technical Analysis Perspective, Is EFTR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Locust Walk Acquisition Stock Split?

Locust Walk Acquisition has split 1 times.

How Many Employees Does Locust Walk Acquisition Have?

Locust Walk Acquisition has 14 employees.

What is the current trading status of Locust Walk Acquisition (EFTR)?

As of 24 Jul 2025, Locust Walk Acquisition (EFTR) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.06.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.